問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Medical University Hospital (在職)

Division of Thoracic Medicine

Division of General Internal Medicine

更新時間：2023-09-19

陳美娟Chen, Mei-Chuan
  • Co-Principal Investigator
  • Clinical Trial Experience (year) -8 years -3 個月

Recruiting Trial

60Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳美娟

List

78Cases

2023-09-01 - 2029-12-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
13Sites

Recruiting13Sites

2023-11-01 - 2035-12-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Recruiting7Sites

2023-11-15 - 2031-12-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
11Sites

Not yet recruiting9Sites

Recruiting1Sites

2023-12-01 - 2027-12-31

Phase I

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Recruiting6Sites

2026-03-20 - 2028-01-27

Phase I

Active
A Phase I, Multicentre, Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab in Adult Participants with Solid Tumours (IMFINZI-subQ)

  • Condition/Disease

    Non-Small Cell Lung Cancer (NSCLC)

  • Test Drug

    Imfinzi Imjudo Subcutaneous Durvalumab rHu (AZD4773)

Participate Sites
4Sites

Not yet recruiting4Sites

2024-02-06 - 2029-08-30

Phase II

-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
9Sites

Not yet recruiting8Sites

Recruiting1Sites

2025-12-11 - 2031-06-30

Phase III

Not yet recruiting
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of GB-0895 Adjunctive Therapy in Adults and Adolescents with Severe Uncontrolled Asthma

  • Condition/Disease

    Severe Asthma

  • Test Drug

    GB-0895

Participate Sites
6Sites

Recruiting6Sites

2024-04-15 - 2033-12-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
12Sites

Not yet recruiting11Sites

2024-04-30 - 2027-04-30

Phase I/II

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting5Sites

2024-05-31 - 2027-05-30

Phase II

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting5Sites

1 2 3 4 5 8
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB